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The objective of the present study is to ﬁnd out the quantitative relationship between progression of liver ﬁbrosis and the levels
of certain serum markers using mathematic model. We provide the sparse logistic regression by using smoothly clipped absolute
deviation(SCAD)penalizedfunctiontodiagnosetheliverﬁbrosisinrats.Notonlydoesitgiveasparsesolutionwithhighaccuracy,
it also provides the users with the precise probabilities of classiﬁcation with the class information. In the simulative case and the
experiment case, the proposed method is comparable to the stepwise linear discriminant analysis (SLDA) and the sparse logistic
regression with least absolute shrinkage and selection operator (LASSO) penalty, by using receiver operating characteristic (ROC)
with bayesian bootstrap estimating area under the curve (AUC) diagnostic sensitivity for selected variable. Results show that the
new approach provides a good correlation between the serum marker levels and the liver ﬁbrosis induced by thioacetamide (TAA)
in rats. Meanwhile, this approach might also be used in predicting the development of liver cirrhosis.
1.Introduction
Chronic hepatitis, characterized by hepatic ﬁbrosis, is recog-
nized as a health problem with a worldwide prevalence, and
itmaygraduallyprogresstowardcirrhosis andhepatocellular
carcinoma which may induce death. Successful and early
treatment of chronic hepatitis can prevent development of
cirrhosis and hepatocellular carcinoma. There are two major
symptoms of chronic hepatitis: necroinﬂammatory activity
and ﬁbrosis. Liver ﬁbrosis is the best sign for predicting the
development of liver cirrhosis [1]. Since there is no corre-
lation between aminotransferase activities and ﬁbrosis, ami-
notransferase activities cannot be used for the diagnosis of
ﬁbrosis. Considering that liver ﬁbrosis is reversible in the
early stage, accurate and early diagnosis of liver ﬁbrosis is
required for better prognosis of chronic hepatitis.
Liver biopsy has to date been the gold standard for the
grading of hepatic inﬂammation and the staging of hep-
atic ﬁbrosis and has been used as the reference standard
method in evaluations of plasma markers of liver diseases
[2]. However, it is an expensive, invasive procedure with
a considerable risk of complications (particularly bleeding)
and a small chance (<1:1000) of death [3]. And liver biopsy
sample is only 1:50000th of the mass of the liver and
therefore causing the risk of false negative. Even with sample
of adequate sized biopsies, cirrhosis may still be missed in
15–30%of liverbiopsies[4]. Due to the limitations ofbiopsy
including the small but signiﬁcant mortality rates, sampling
error, inter- and intraobserver variation in pathology report-
ing, and provision of a static picture of liver architecture in
a dynamic disease process, it is still necessary to look for
alternative approaches. Moreover, to evaluate drug eﬃcacy,
it is essential to establish appropriate animal models of
liver ﬁbrosis. Since establishing an animal model is time-
consuming, usually lasting 8 to 12 weeks, histopathologic
examination may lead to the consumption of animals, and
the testing small proportion cannot reﬂect the condition of
whole population. All these would increase the cost and
decrease theeﬃciencyand reliability oftheresearch. In order
to build appropriate animal models for liver ﬁbrosis, also
it is necessary to develop a reliable and accurate method to
diagnose liver ﬁbrosis quickly.2 Journal of Biomedicine and Biotechnology
Thesearch ofanoninvasive methodtoassess liverﬁbrosis
has encouraged the development of various approaches.
Transient elastography for the noninvasive measurement of
liver stiﬀness was developed [5–7]. Currently, it is notable
that monitoring serum markers of liver ﬁbrosis could oﬀer
an attractive alternative to liver biopsy, as it allows dynamic
calibration of ﬁbrosis eﬃcaciously. Liver ﬁbrosis is charac-
terized by an overall increase of the extracellular matrix,
mainly produced by hepatic stellate cells (HSCs) [8, 9],
which undergo a phenotypic switch induced within the
inﬂammation process by numerous cells and cytokines. A
number of potential serum markers of ﬁbrosis and cirrhosis
have been used in the diagnosis of a variety of chronic liver
diseases.
Therefore, monitoring a variety of plasma markers, espe-
cially collagen-related biomarkers such as aminoterminal
peptide of procollagen III (PIIINP), is a novel approach for
liver ﬁbrosis diagnosis. In general, there are many plasma
markersidentiﬁedbutsomeofthemstillhavenotbeendeter-
mined yet. So constructing a sparse classiﬁcation for the pro-
gression of liver ﬁbrosis based on detected plasma markers
has attracted much attention. A novel method is linear dis-
criminant analysis with stepwise variable selection. Guyon
etal. [10] proposeda recursive feature elimination technique
with support vector machine to analyze gene expression
data. Rocke and Nguyen [11] raised dimension reduction of
microarray-based classiﬁcation. Li et al. [12] introduced two
bayesian approaches with technique of automatic relevance
determination for the same problem.Debashis and Arul[13]
suggested that linear discriminant function by optimal scor-
ing with LASSO was an alternative approach. Sparse Fisher’s
linear discriminant analysis, suggested by Qiao et al. [14],
was also an excellent method.
The aim of this study, therefore, is to develop classi-
ﬁcation rules based on the consideration of measures of
diagnosticaccuracy.Inparticular,weareinterestedinﬁnding
liver ﬁbrosis that can discriminate between two populations.
Our solution was to combine the problems of variable
selection and classiﬁcation. We suggested an approach for
classiﬁcation using the smoothly clipped absolute deviation
penalty
￿SCAD) [15] approach with logistic regression
[16]. We compared it with the stepwise linear discriminant
analysis (SLDA) and sparse logistic regression (SLR) with
least absolute shrinkage and selection operator (LASSO-)pe-
nalized function [17, 18]. At last, we analyzed the sen-
sitivity of these methods using the receiver operating charac-
teristic (ROC). Considering the small sample size, we ﬁt the
ROC curve and compute the area under the curve (AUC)
using Bayesian bootstrap [19, 20].
2.Materialsand Method
2.1. Animals. Twenty-eight Sprague-Dawley (SD) rats were
provided from SLAC Laboratory Animal Co.ltd (Shanghai,
China, SCXK: 2007-0005). The rats were maintained under
speciﬁc-pathogen-free conditions, with a constant tempera-
ture ranging between 25 and 27◦C, and a constant humidity
ranging between 45 and 50% at animal laboratory of China
Pharmaceutical University. Animal care was in accordance
with the guidelines of the animal laboratory of China Phar-
maceutical University.
2.2. Induction Of Liver Fibrosis. The modeling method is in
accord with Imanishi et al. [21]a n dK u r i y a m ae ta l .[ 22].
The rats were randomly divided into 4 subgroups: (I) model
group (8 weeks, n = 8), (II) model group (12 weeks, n = 8),
(III) normal control group (8 weeks
￿ n = 6), and (IV)
normal control group (12 weeks, n = 6). All rats were
observed at 8th week and 12th week after TAA treatment.
Rats in the model subgroup were injected intraperitoneally
(i.p) with TAA 3 consecutive days per week and lasted for
8 weeks at a dose of 6% TAA 200mg/kg as an initial dose.
The doses after the ﬁrst time were modiﬁed according to
weekly weight and AST changes in response to TAA during
the induction. Rats in normal control groups were treated
with saline. After the ﬁnal administration in the8thand 12th
weeks, blood samples were collected and serum was sepa-
rated by centrifugation at 4◦Ca n dk e p ta t−20◦Cf o rf u r t h e r
analysis. Then all rats were sacriﬁced under anesthesia. The
livers were washed with cold saline, and a part of the right
hepaticlobularwasremovedandstoredinliquidnitrogenfor
content detection of hydroxyproline. The remaining part of
therighthepaticlobularwasmadeintoslicesforpathological
diagnosis. Several serum markers and liver function indices
studied in clinical research were measured at the 8th and
12th weeks, respectively. There are many serum markers
reported astheliverfunctionindices.Afterconsideration,we
ultimately chose hyaluronan (HA), serum laminin (LN),
collagen Type I (Col I), IV collagen (IVC), procollagen III
(PC-III), aspartate aminotransferase (AST), albumin (Alb),
hydroxyproline (Hyp), total protein (TP), and total bilirubin
(T.Bil) [7, 23] in this study. The liver tissue slices were
observed and diagnosed by HE, Masson-trichrome staining,
and transmission electron microscope. Then the relationship
between the serum index and the occurrence of liver ﬁbrosis
was analyzed by statistics model.
2.3. Statistics Model and Solution
2.3.1. Statistics Model. Let {(x1, y1),(x2, y2),...,(xn, yn)} be
input-output pairs of a given data set
￿ where xi in Rp is
variable levels of plasma markers and yi in {0,1} is the type
of liver ﬁbrosis occurs or not identiﬁed in liver biopsy. Here,
nisthenumberofliverbiopsyand p is thenumber ofplasma
markers. For binary logistic regression, we can write it as
πi(x) = pr
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Further, the SCAD-penalized maximum likelihood function
is
l
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for some a>2a n dθ>0.
In general, pλjmay be diﬀerent coeﬃcients. Here, we
make λ = λj. In other words, the same penalty function is
applied to each component of β [24]. Generally, λ can be
selected by GCV. Another alternative penalized function is
the least absolute shrinkage and selection operator [17].
They suggested the penalized function couldbe selected with
pλj = λj|βj|. The algorithm can be carried with least angle
regression [25]. Making λ = λj, the penalized maximum
likelihood with LASSO is
n−1l
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Once the regression coeﬃcient β is estimated, the classiﬁer is
constructed as follows. Let c(i | j) be the cost of classifying
an observation to the i class when the true class is j.T h e n ,
a new tissue sample with plasma markers x is classiﬁed into
class c(x), where c(x) becomes
c(x) = argmin
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i | j
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. (6)
In practice, c(i | j) are equal which is most frequent. So
minimum c(x) is equal to arg maxj pr(y = j|x).
2.3.2. Solution. In this study, we principally discuss the
SCAD penalized. It can be locally approximated by a quad-
ratic function as follows:
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Then, the penalized log-likelihood can be locally approxi-
mated by
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We then estimate β as follows:
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Y = (y1, y2,..., yn)
 ,
 
= (π1,π2,...,πn), V = diag(πi ·(1−
πi)), and X is an index matrix. Given the good initial value
β0, the penalized maximum likelihood can be as eﬃcient as
the fully iterative procedure.
2.3.3. Simulation Studies. In this subsection, we numerically
compare the proposed approach of variable selection and
classiﬁcation methods with SLDA and LASSO methods.
We simulate 1000 datasets when n = 20, 40, 60, 100
respectively, from the model Y ∼ Bernoulli{π(xTβ)},w h e r e
π(u) = exp(u)/(1 + exp(u)) and β = (3,1.5,0,0,2,0,0,0).
The previous six components of x come from a standard
normal distribution. The correlation between xi and xj is
ρ|i−j| with ρ = 0.5. The last two components of x are
independently and identically distributed as a Bernoulli
distribution with probability of success 0.5. All covariates
are standardized. This model was used in Tibshirani et al.
[17]. The classiﬁcation standard is based on the probability
argmax pr(y = j|x).
Deﬁne
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n
 
.
(13)
The true classiﬁcation ratio is computed via 1000 Monte
Carlo simulations. The summary of simulation results is
depicted in Table 1.
Table 1 shows that the true classiﬁcation ratio associates
with thesample size n. With the increase of the sample size n,
the true classiﬁcation ratio tends to one. Another important
keypoint:threemethodsareallworkingwellforlargesample
size n.
3.Result
3.1. Histopathology of Liver Fibrosis. Typical liver ﬁbrosis was
induced after 8 weeks of TAA treatment, with the hepatoﬁ-
brosis pathological characteristics of ﬁbroblast extending
around from central venous or portal area, forming the ob-
vious ﬁber separator without the formation of false lobules.
From the light microscope, it could be seen that pathological
slice of normal animals had clear lobule, there was no edema
or denatured fat in liver cells, and Sinus hepaticus had4 Journal of Biomedicine and Biotechnology
Table 1: True classiﬁcationratio simulationsresults.
n SLDA SLR-LASSO SLR-SCAD
MedTrue MeanTrue MedTrue MeanTrue MedTrue MeanTrue
20 0.95 0.9335 0.9 0.8559 0.9 0.8974
40 0.95 0.9558 0.925 0.9285 0.925 0.9254
60 0.9667 0.9657 0.9667 0.9546 0.95 0.9488
100 0.98 0.9728 0.98 0.9729 0.98 0.9687
SLDA: stepwise linear discriminantanalysis.
SLR-LASSO: sparse logisticsregression-least absolute shrinkage and selection operator.
SLR-SCAD: sparse logistics regression-smoothly clipped absolute deviation penalty.
×100
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Figure 1: Progression of TAA-induced liver ﬁbrosis in SD rats was assessed by HE and Masson-Trichrome staining at diﬀerent time points
of treatment. (a–c) HE staining,(a) Nomal, (b) 8w Model, and (c) 12w Model, (d–f) Masson-trichromestaining,(d) Nomal,(e) 8w Mode,
and (f) 12w Mode.
Table 2: The level of AST in liver tissue during induction (x ±s).
Group Week AST (IU/L)
Normal 8w 37.33 ±6.94
12w 36.27 ±6.21
Model 8w 67.37 ±8.83∗∗
12w 40.8 ±7.26
∗∗P<. 05, compared to the normal group.
no expansion and congestion (Figures 1(a) and 1(d)). The
pathological slice of model animals had obvious ﬁbroplasias
extending from the central venous or portal area to sur-
rounding area, which formed the clear ﬁbrous septa. The
liver cells had mild steatosis with lipid droplet and vacuoles
accompanied by mild bile duct hyperplasia (Figures 1(b),
1(c), 1(e),a n d1(f)).
3.2. Serum Markers Analysis. According to Table 3,t h e r ew a s
am a j o rd i ﬀerence between the normal group and control
group in several serum markers and liver function indices
such as HA
￿LN, IVC, and I Collogen. During the 1st–
4th weeks, AST activity reached the peak and there is no
signiﬁcant diﬀerence (P>. 05) in the 5th to 8th weeks
(Table 2). In Figure 2, it is shown that after peak value AST
activity gradually decreased and returned to normal during
the 12th week. As a matter of fact the level of AST in human
goes up obviously during acute hepatitis, and it correlate
with the severity of the disease. Then the activity of AST
decreasesduring thecourseofliverﬁbrosis [26].ASTactivityJournal of Biomedicine and Biotechnology 5
Table 3: The content of determined parameters in the serum during TAA induction (x ±s).
Group (A/T) ( AST) (Hyp) (IVC) ( LN ) (PC-III)
(%) (IU/L) (ng/mL) (ng/mL) (ng/mL) (ng/mL)
Normal 46.53 ±12.13 36.80 ±6.94 137.14 ±12.98 18.14 ±3.08 10.28 ±7.49 7.44 ± 4.38
Model 40.45 ±11.40 54.09 ±13.26 193.96± 14.29∗∗ 21.60 ± 4.07∗∗ 17.78± 6.68∗∗ 10.88 ±3.25∗∗
Group (Col I) (HA) (T.Bil) (A/G) (Alb) (TP)
(ng/mL) (ng/mL) (ng/mL) (%) (mg/mL) (mg/mL)
Normal 31.48 ±5.27 5.26 ±5.49 5.55 ±1.19 83.99 ±14.45 37.27 ±11.56 79.62 ±8.64
Model 48.10 ±14.68∗∗ 16.86 ±8.6∗∗ 4.91 ±1.75 73.52 ±11.92 32.09 ±9.62 79.28 ±7.69
∗∗P<. 05, compared to the normal group.
Table 4: List of covariates for plasma markers.
Covariates Plasma markers
Y Diagnosis the degree liver ﬁbrosis by using the
pathological diagnosis
x1 Albumin ratio of total protein (A/T)
x2 Aspartate aminotransferase(AST)
x3 Hydroxyproline (Hyp)
x4 IV collagen (IVC)
x5 Serum laminin (LN )
x6 III collagen (PC-III)
x7 I collagen (Col I)
x8 Hyaluronan (HA)
x9 Total Bilirubin (T.Bil)
x10 Albumin ratio of the globulin (A/G)
x11 Albumin (Alb)
x12 Total protein (TP)
Table 5: List of variable selection results.
SLDA SLR-LASSO SLR-SCAD
Hydroxyproline Hydroxyproline Hydroxyproline
I collagen LN LN
Hyaluronan IV —
—H y a l u r o n a n —
Table 6: List of classiﬁcation true rates.
SLDA SLR-LASSO SLR-SCAD
Classiﬁcation true rates (%) 96.15 92.31 96.15
of control group was signiﬁcantly higher than the normal
group and decreased slightly in the 12th week without TAA
for four weeks which agrees with the literature [27]. At last
typical liver ﬁbrosis was induced after 8 weeks of TAA.
3.3. Application. We applied the proposed sparse logistic
regressionwithSCAD,LASSO,andSLDAtotheclassiﬁcation
ofliverﬁbrosis. Thedatasetconsisted of26observations. The
binary response variable Y is 1 for those rats who have liver
ﬁbrosis and 0 otherwise. All the twelve covariates are consid-
ered. All covariates’ meanings were listed in Table 4.
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Figure 2: The change of AST during induction.
Carrying out the procedure, including the SLDA, SLR-
SCAD, SLR-LASSO, then the outcome about the selected
variable and the classiﬁcation true rates were obtained, re-
s p e c t i v e l y ,a c c o r d i n gt oT a b l e s5 and 6.
3.4. Test Signiﬁcance. The receiver operating characteristic
(ROC)curveisan excellent method totest thesigniﬁcance of
selectedvariables.TheROCcurveisaplotofthetruepositive
fraction (TPF) as a function the false positive fraction (FPF),
or sensitivity versus one minus speciﬁcity, and is obtained
by varying the threshold criterion distinguishing between
apositiveandnegativediagnosis. Forexample,thediagnostic
variables X ∼ F are for the population without liver ﬁbrosis
and Y ∼ G are for those with liver ﬁbrosis, where F and
G are the distribution functions. Some features such as the
invariance property and interpretation of the area under
the curve (AUC) as pr(Y>X )m a k et h eR O Ca n a l y s i s
extremely popular in diagnostics research. Generally, the
selected variables are sensitive for the classiﬁcation if the
AUC > 0.7. However, estimation of AUC for the ROC curve
is very diﬃcult, especially for the small sample size. Here,
we use the Bayesian bootstrap (BB) estimation of AUC,
proposed by Kuriyama et al. [22], to test the variables in
SLDA, LASSO, and SCAD. The AUC calculation results are
shown in Table 7, displaying the sensitivity for classiﬁcation
variable Y.F i g u r e3 described these covariates’ ROC curves.6 Journal of Biomedicine and Biotechnology
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Figure 3: BB estimates of ROC curves for diagnostic covariates for markers.Journal of Biomedicine and Biotechnology 7
Table 7: ROC curve analysis.
x1 x2 x3 x4 x5 x6
AUC 0.3134 0.5869 0.7989 0.1685 0.7632 0.3450
x7 x8 x9 x10 x11 x12
AUC 0.6510 0.8173 0.3729 0.3169 0.3733 0.4569
The ROC of x3, x5,a n dx8 a r em o r et h a n0 . 7 ,a n dt h e y
represent the hydroxyproline, LN, and hyaluronan, respec-
tively.
As shown in Table 7 and Figure 3,w ec o m et oac o n -
clusion that some covariates may be very important for
diagnosis of the occurrence of liver ﬁbrosis, such as hydrox-
yproline, LN, hyaluronan, as the AUCs for these covariates
are more than 0.7.
Fortunately, these covariates are all selected by the three
statisticalmodels.ThoughSLR-SCADchoseonlytwocovari-
ates, it gets higher diagnostic accuracy, equaling to SLDA,
better than SLR-LASSO, as shown in Tables 5 and 6.I t
elucidates that by using SLR-SCAD we could obtain high
diagnostic accuracy with fewer serum indices so as to save
theexperimentcost.Meanwhile,theSLDAandSLAR-LASSO
also display well. But their high diagnosis accuracy needs
more variables to be selected.
4.Discussionand Conclusion
It has been thought that the research on liver ﬁbrosis is
entering a new era of the whole wound and heal reaction
[28]. The ideal animal model, which is a reliable and re-
producible on hepatic ﬁbrosis, should have the basic patho-
logical characteristics with the same phase change on pathol-
ogy as human liver ﬁbrosis. However, there are some defects
on detection methods in the process of establishing animal
model. Considering the limitation of traditional test method
inmodeling,weproposeanalternativeapproachtoconstruct
the quantiﬁcation between ﬁbrotic condition and serum
indices. Since accurate diagnosis of liver ﬁbrosis remains
ad i ﬃcult and crucial problem in both the animal models
and patients, an ongoing challenge is to identify new prog-
nostic markers that are directly related to liver ﬁbrosis and
that can more accurately predict the likelihood of gaining
l i v e rﬁ b r o s i s .H e r ew ei n t r o d u c ean e wa p p r o a c ht ot h e
jointing problemsof simultaneous classiﬁcation and variable
selection utilizing the sparse logistics regression with SCAD-
penalized function. The proposed method is applied in our
study to analysis the data of plasma makers for diagnosis of
the liver ﬁbrosis in rat model and to determine the occur-
rence of cirrhosis.
In this study, the pathological section results were used
to determine whether the reliable animal model with liver
ﬁbrosis induced by the dose individualization of TAA was
established successfully. Despite, there is, diﬀerence between
liver biopsy of human in clinic and pathological section of
dead animal, they are both expensive, invasive and have
a chance of death, especially the inevitable death of animals.
It is because that the pathological slice from the whole rat’s
liver could supply the highest accuracy that the results can
be as the standard to verify the outcome of statistical model.
There is no doubt that sacriﬁcing animal life attributes to
signiﬁcant mortality rates and disobeys the morality and
ethics. Our proposed method by using serum indices may
indeed greatly decrease the consumption of a lot of animals
when used in hepatic drug screening.
Monitoring a variety of plasma markers, especially the
levels of collagen-related markers, is becoming a novel ap-
proach of liver ﬁbrosis diagnosis with simple procedure and
high sensitivity and accuracy. According to Table 1,t h e
novel SLR-SCAD method performs as well as other well-
known methods such as SLDA and SLR-LASSO in statistical
classiﬁcationand variableselection.Theyallperform wellfor
the ﬁxed sample size. The SLR-SCAD achieved higher classi-
ﬁcation ratio by the two selected variables, hydroxyproline
and LN, which are reasonable by the veriﬁcation of ROC
curve. The two variables also have signiﬁcant sense in clinic.
IfSLDAandSLR-LASSOwanttoobtainhigherclassiﬁcation,
they need to test more serum indices. In addition, it is
mentioned that the SLDA method has its own drawback
especially when the variables have collinearity [26, 29].
Compared with the SLDA and SLR-LASSO methods, SLR-
SCAD is quite beﬁtting for penalized regressions.
It will be a very useful approach to determine the occur-
rence of liver ﬁbrosis in animals based on statistic models
with fairly high diagnosis accuracy and without loss of
animals. The occurrence of liver ﬁbrosis can be eﬀectively
e s t i m a t e di nr a t sb yu s i n go u rp r o p o s e dS L R - S C A Dm e t h o d
with the right serum indices. In summary, we propose a new
method by combining the analysis of serum index of ﬁbrosis
and statistic model which represent a reliable diagnostic and
prognostic approach of liver disease. It could be beneﬁcial
to extend this study to other ﬁelds where classiﬁcation and
many variables exist.
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